| Name: | Description: | Size: | Format: | |
|---|---|---|---|---|
| 271.87 KB | Adobe PDF |
Advisor(s)
Abstract(s)
Alzheimer's disease (AD) is the dominant dementia condition of our society with great social and economic impact. One of the major pathological changes is the formation of extracellular insoluble deposits of β-amyloid protein (Aβ) in plaques. Pathological changes are often accompanied by neuroinflammation, abnormal activity of the neural network, dysfunction, degeneration and loss of neurons. Moreover, there is no current test capable of providing accurate diagnosis of AD and, besides that there is no treatment of prevention available, only a way to delay its progression, so the early diagnosis is the key in present. Research activities targeting such possibility include the identification of biomarkers in several biological fluids that may turn out an important means to diagnosis within future, mostly if these are found in peripheral blood (avoiding more invasive procedures). Thus, the main goal of this proposal is to develop novel, low cost (bio)sensing-devices with an aptamer as a biorecognition element of AD biomarker detection, Aβ42, in point-of-care.
Description
Keywords
Alzhemier’s disease Aβ-42 Electrochemical biosensor
Citation
Mendes, F., Sales, G., & Moreira, F. (2018). Development of an electrochemical biosensor for an Alzheimer biomarker detection in Point-of-Care. Book of abstracts of the III Encontro de Biotecnologia Medicinal/ I Iberian Congress on Medicinal Biotechnology, 30. https://paginas.ess.ipp.pt/ebtm/2018/3EBtM_BookOfAbstracts.pdf
Publisher
Escola Superior de Saúde P.Porto